{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "62.39",
    "chg": 2.17,
    "chgp": "3.6%",
    "dir": 1,
    "prev_price": "60.22",
    "mcapval": "47.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE499G01013",
    "curr_date": "Apr 11, 12:48 PM",
    "curr_time": "00:14 AM",
    "bse_nse_vol": "912 ",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gujarat Terce Laboratories Reports 149% PAT Growth in Q3 FY24-25 Financial Results",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-terce-laboratories-reports-149-year-on-year-growth-in-half-year-pat-for-fy24-25-746335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/GujaratTerceLab_quaterlyResult_352274.png",
        "date": "2025-02-04 19:31:40",
        "description": "Gujarat Terce Laboratories has announced its financial results for the quarter ending December 2024, reporting a Profit After Tax of Rs 2.49 crore for the half-year, marking a 149% year-on-year increase. This performance highlights the company's strong profitability and operational effectiveness in the competitive pharmaceutical sector."
      }
    ],
    "total": 61,
    "sid": "890385",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Apr-2025",
      "details": "Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulations 2018.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Mar-2025",
      "details": "Intimation on Closure of Trading window from 1st April 2025 until 48 hours after the declaration of the Companies Audited Financial Results for the quarter and financial ended 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
      "datetime": "12-Mar-2025",
      "details": "Share Transfer Agent of the Company is in receipt of completed documents for issuance of duplicate share certificate.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Gujarat Terce Laboratories Reports 149% PAT Growth in Q3 FY24-25 Financial Results

2025-02-04 19:31:40

Gujarat Terce Laboratories has announced its financial results for the quarter ending December 2024, reporting a Profit After Tax of Rs 2.49 crore for the half-year, marking a 149% year-on-year increase. This performance highlights the company's strong profitability and operational effectiveness in the competitive pharmaceutical sector.

Read More

View All News